Addex Therapeutics Ltd (ADXN)
| Market Cap | 9.20M |
| Revenue (ttm) | 2.24M |
| Net Income (ttm) | -12.34M |
| Shares Out | 1.52M |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,867 |
| Open | 5.85 |
| Previous Close | 5.85 |
| Day's Range | 5.74 - 6.60 |
| 52-Week Range | 5.00 - 45.60 |
| Beta | 1.61 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 29, 2023 |
About ADXN
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with ... [Read more]
Financial Performance
In 2022, ADXN's revenue was 1.44 million, a decrease of -54.18% compared to the previous year's 3.15 million. Losses were -20.80 million, 35.5% more than in 2021.
Financial numbers in CHF Financial StatementsNews
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 20, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modu...
Addex Creates Treasury Shares
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 14, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modu...
Addex Reports Q3 2023 Financial Results and Provides Corporate Update
ADX71149 Phase 2 epilepsy clinical study completes recruitment of patients, with top line results expected in Q2 2024 mGlu2 NAM cognition program receives a €4 million Eurostars grant CHF 4.8M ($5.2M)...
Addex Convenes Extraordinary General Meeting
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 28, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modul...
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023
Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
Top line results expected in Q2 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 14, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical comp...
Addex Regains Nasdaq Listing Compliance
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 8, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-b...
Addex Announces Participation in the Bio-Europe 2023 Conference
Geneva, Switzerland, November 2, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today ...
Addex Completes ADS Ratio Change
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 20, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-b...
Addex Announces Plan to Implement ADS Ratio Change
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-ba...
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
Addex led consortium wins Eurostar s grant to deliver clinical candidates to treat mild neurocognitive disorder s Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 20, 202 3 - ...
Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
Geneva, Switzerland, September 6 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, tod...
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
Cohort 1 is completed , and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage ...
Addex's Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
Landmark study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological functions First time mGlu5 linked to post - stroke functional recovery Ad Hoc Announcement Pursuant ...
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update
ADX71149 Phase 2 e pilepsy c linical s tudy Cohort 2 continues recruiting following the Independent Interim Review Committee (IRC) recommendation Indivior GABAB PAM collaboration extended to June 2024...
Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023
Geneva, Switzerland, August 3 , 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today a...
Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration
Discovery c ollaboration on track to deliver clinical candidate s for IND enabling studies in 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 3 , 202 3 - Addex Therapeutics...
Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder
Data published in Neuropharmacology shows mGlu2 PAM s attenuate oxycodone use and potential as a novel treatment f or opioid use disorder Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland...
Addex Increases Issued Share Capital to Create Treasury Shares
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 1 5 , 202 3 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric mo...
Addex Shareholders Approve All Resolutions at Annual General Meeting
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 1 , 202 3 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modu...
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 1 8 , 202 2 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric mod...
Addex Reports Q1 2023 Financial Results and Provides Corporate Update
ADX71149 Phase 2 e pilepsy c linical s tudy's i ndependent i nterim r eview c ommittee (“IRC”) r ecommends c ontinuing s tudy CHF 5.6M ($ 6.1 M) of cash and cash equivalents at March 31, 202 3 Ad Hoc...
Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study's Independent Interim Review Committee Recommends Continuing Study
Cohort 1 progressing through P art 2 Cohort 2 recruiting patients Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10 , 202 3 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical...
Addex Convenes Annual General Meeting 2023
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 5, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-...
Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023
Geneva, Switzerland, May 4 , 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today anno...